Imagion Biosystems engages Starfish Medical to develop MagSense
US-based bio imaging products developer Imagion Biosystems has signed a service agreement with StarFish Medical for its MagSense instrument development.
Located in Canada, StarFish Medical will be responsible for the design and development of the MagSense platform for clinical applications.
The MagSense instrument employs magnetic field sensors to identify the remnant magnetic relaxation of a tumour targeting antibody-coated nanoparticles administered via intravenous injection.
These nanoparticles circulate through normal blood flow and bind to the target tumour cell, allowing the MagSense tool to detect the accurate localisation of the bound particles.
With operations in Victoria, British Columbia and Toronto, Ontario, Canada, StarFish Medical is a design, development and contract manufacturing company catering to cardiovascular, digital health, IVD, ophthalmology, optics, and ultrasound segments.
Under the collaboration, StarFish Medical will aid in translating Imagion Biosystems’ prototype into a product that can meet regulatory requirements for use in human testing.
StarFish will commence the first phase in the development of the industrial design, and will initially deliver a mockup of the instrument before proceeding to the development of prototypes for human studies and market development.
Imagion Biosystems CEO Robert Proulx said: “We chose StarFish because of their depth in medical device engineering and experience in magnetic imaging systems.
“In parallel with this design project, we continue to work towards cGMP manufacturing of our formulated nanoparticles, followed by stability and toxicity studies.
“The team at Imagion remains focused on pursuing these goals expeditiously and cost-effectively to get to first-in-human testing.”
The firm develops bioimaging and nanomagnetic detection systems for early and accurate identification of diseases such as cancer.
Its MagSense technology is expected to optimise patient care and decrease mortality rates in different cancer indications.